TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20478402
Drug: n‐acetylcysteine pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐acetylcysteine pretreatment before a culture‐guided antibiotic regimen
Study: 17628824
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of sodium bicarbonate (NaHCO3)
Study: 17628824
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of calcium carbonate (CaCO3)
Study: 12027195
Drug: Delirium-free protocol
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delirium-free protocol (DFP) group with diazepam injection at 20:00 h and continuous infusion of flunitrazepam and pethidine for 8 hours for the first three nights postoperatively
Study: 2286596
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg bd, intravenous for 3 days followed by oral for 7-10 days)
Study: 2286596
Drug: Amoxycillin/clavulanate (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate (intravenous for 3 days followed by oral for 7-10 days)
Study: 23868279
Drug: Modified constraint‐induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint‐induced movement therapy
Study: 23868279
Drug: Dose‐matched conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose‐matched conventional treatment
Study: 17568029
Drug: Fluconazole 6
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 6 mg/kg
Study: 17568029
Drug: Fluconazole 3
Normalized name: Fluconazole 3 mg/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 3 mg/kg
Study: 12113651
Drug: Topical pimecrolimus
Normalized name: pimecrolimus Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pimecrolimus 1.0% cream applied twice daily for 3 weeks in adults
Study: 12113651
Drug: Topical pimecrolimus
Normalized name: pimecrolimus Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pimecrolimus 1.0% cream applied twice daily for 6 weeks in infants and children
Study: 12113651
Drug: Topical pimecrolimus
Normalized name: pimecrolimus Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pimecrolimus 1.0% cream
Study: 12113651
Drug: Topical pimecrolimus
Normalized name: pimecrolimus Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pimecrolimus 1.0% cream (intermittent long-term use)
Study: 12113651
Drug: Topical pimecrolimus
Normalized name: pimecrolimus Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pimecrolimus 1.0% cream for 1 year
Study: 10569156
Drug: Topical intrastromal
Normalized name: ALCOHOL 80 mL in 100 mL INTRACORONAL, DENTAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical intrastromal steroid (prednisolone sodium phosphate 1% solution) applied on the undersurface of the cap immediately after it was reflected.
Study: 10569156
Drug: Standard LASIK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard LASIK medication protocol (no steroid application).
Study: 8545530
Drug: Flumazenil 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 1.0 mg
Study: 31975316
Drug: Red clover
Normalized name: Red clover
DrugBank: Trifolium pratense pollen (DB15530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red clover preparation (Promensil® Forte) 80 mg/day for 24 months
Study: 31975316
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one oral tablet/day without active ingredient)
Study: 22071707
Drug: Uncalibrated protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncalibrated protein intake (g/d) (20% increment)
Study: 22071707
Drug: Biomarker-calibrated protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker-calibrated protein intake (g/d) (20% increment)
Study: 22071707
Drug: Uncalibrated protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncalibrated protein intake (g/d) (20% increment) after adjustment for BMI
Study: 11674922
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treated only with drugs)
Study: 1357295
Drug: Intravenous adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous adrenaline (0.1 microgram/kg)
Study: 3908500
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of ciramadol
Study: 3908500
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of ciramadol
Study: 3908500
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of codeine
Study: 23979965
Drug: Besifovir 90
Normalized name: Besifovir
DrugBank: Besifovir (DB15671)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besifovir 90 mg daily
Study: 23979965
Drug: Besifovir 150
Normalized name: Besifovir
DrugBank: Besifovir (DB15671)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besifovir 150 mg daily
Study: 16230074
Drug: Entecavir 0.5
Normalized name: entecavir 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 0.5 mg daily
Study: 12654753
Drug: Azithromycin 1000
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1000 mg once daily for 3 days
Study: 11314681
Drug: Ritanserin 5
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin 5 mg
Study: 1715125
Drug: Imazodan 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imazodan 2 mg administered twice daily
Study: 1715125
Drug: Imazodan 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imazodan 5 mg administered twice daily
Study: 1715125
Drug: Imazodan 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imazodan 10 mg administered twice daily
Study: 6869493
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional therapies continued)
Study: 26821623
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg intravenous CsA
Study: 24556041
Drug: FOLFOX (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX (oxaliplatin 85 mg/m², leucovorin 200 mg/m², bolus fluorouracil 400 mg/m², infusional fluorouracil 1600 mg/m²)
Study: 24556041
Drug: Fluorouracil and
Normalized name: Fluorouracil and salicylic acid only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil and cisplatin (fluorouracil 1000 mg/m² per day for 4 days and cisplatin 75 mg/m² on day 1)
Study: 16134467
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment for high-risk prethreshold ROP
Study: 20385926
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment for Type 1 eyes
Study: 20385926
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment for Type 2 eyes
Study: 16157829
Drug: PSA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA levels 0 to 0.49 ng/mL
Study: 16157829
Drug: PSA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA levels 0.50 to 0.99 ng/mL
Study: 16157829
Drug: PSA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA levels 1.00 to 1.49 ng/mL
Study: 16157829
Drug: PSA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA levels 1.50 to 1.99 ng/mL
Study: 16157829
Drug: PSA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA levels 2.00 to 2.49 ng/mL
Study: 16157829
Drug: PSA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA levels 2.50 to 2.99 ng/mL
Study: 16157829
Drug: PSA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA levels 3.00 to 3.99 ng/mL
Study: 16157829
Drug: PSA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA levels 4.00 to 6.99 ng/mL
Study: 16157829
Drug: PSA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA levels 7.00 to 9.99 ng/mL
Study: 16157829
Drug: PSA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA levels 10.00 ng/mL or higher
Study: 16157829
Drug: Initial PSA
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial PSA level less than 1 ng/mL
Study: 7752005
Drug: Pulse doses
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse doses of dexamethasone, 0.5 mg/kg per day, divided twice daily for 3 days at 10-day intervals
Study: 1578091
Drug: Vitamins B1,
Normalized name: vitamins B1,B2,B3,B5,and B6 100 mg-2 mg-100 mg-2 mg-2 mg/mL INJECTION VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins B1, B2, and B6 (10 mg each)
Study: 31125491
Drug: Olmutinib 100-300
Normalized name: olmutinib
DrugBank: Olmutinib (DB13164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmutinib 100-300 mg
Study: 25189917
Drug: Complementary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary treatment with sodium selenite, proteolytic plant enzymes and Lc-lectin
Study: 22519543
Drug: Subcutaneous nadroparin
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous nadroparin calcium (200 I.U./kg/day) for 6 weeks
Study: 22519543
Drug: Oral pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pentoxifylline (control)
Study: 17919374
Drug: Hypocaloric and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric and hypo-nitrogen parenteral nutrition (PN) with 18 (range 16-20) kcal x kg(‐1) x d(‐1) and nitrogen 0.10 (0.09-0.11) g x kg(‐1) x d(‐1)
Study: 17919374
Drug: Hypocaloric and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric and hypo-nitrogen parenteral nutrition (PN)
Study: 17919374
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving PN with 30 (28-32) kcal x kg(‐1) x d(‐1) and nitrogen 0.20 (0.19-0.21) g x kg(‐1) x d(‐1)
Study: 10221413
Drug: Meropenem (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (0.5 g/8 h)
Study: 10221413
Drug: Imipenem/cilastatin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (0.5 g/6 h)
Study: 26521190
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg furosemide with HSS
Study: 26521190
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg furosemide with HSS
Study: 26521190
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg furosemide with HSS
Study: 23480923
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5mg/kg) and ketamine (5mg/kg)
Study: 23480923
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5mg/kg), acetaminophen (10mg/kg), and codeine (1mg/kg)
Study: 22258912
Drug: 1-hour psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour psychoeducational group therapy
Study: 22258912
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (no group therapy)
Study: 19267777
Drug: MMF (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF (2 g/day)
Study: 19267777
Drug: SRL (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRL (15 mg loading dose, 5 mg for 7 days followed by 2 mg/day)
Study: 19267777
Drug: PRED dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRED dose reduction
Study: 19267777
Drug: TAC drug
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAC drug exposure
Study: 19267777
Drug: SRL drug
Normalized name: ExoSCRT Derma Signal Kit SRLV KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRL drug exposure
Study: 7940710
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral acyclovir (800 mg 4 times a day) for 3 months
Study: 7940710
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir (5 mg/kg twice a day for 14 days) followed by high dose oral acyclovir for 3 months
Study: 7059416
Drug: Both compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both compounds
Study: 26081985
Drug: AmBisome 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome 10 mg/kg day one (single dose)
Study: 26081985
Drug: AmBisome 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome 10 mg/kg day one and AmBisome 5 mg/kg day three (two doses)
Study: 26081985
Drug: AmBisome 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome 10 mg/kg day one, and AmBisome 5 mg/kg days three and seven (three doses)
Study: 26081985
Drug: AmBisome 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome 3 mg/kg/d for 14 days
Study: 18442788
Drug: Dzherelo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dzherelo (50 drops twice per day)
Study: 14700111
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg 30-45 minutes preoperatively
Study: 14700111
Drug: Placebo 30-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 30-45 minutes preoperatively and diclofenac 100 mg at induction
Study: 1421679
Drug: Velnacrine 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velnacrine 450 mg/d
Study: 1421679
Drug: Velnacrine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velnacrine 300 mg/d
Study: 1421679
Drug: Velnacrine 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velnacrine 225 mg/d
Study: 1421679
Drug: Velnacrine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velnacrine 25 mg, 50 mg, 100 mg (twice daily)
Study: 26809849
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches (5-week supply: 3 weeks of 21 mg, 1 week of 14 mg, 1 week of 7 mg)
Study: 26809849
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nicotine patches or other intervention)
Study: 26222318
Drug: Linaclotide 145
Normalized name: LINACLOTIDE 145MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linaclotide 145 μg
Study: 27903339
Drug: Goal-directed hemodynamic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed hemodynamic management group (G group, n=45)
Study: 27903339
Drug: Goal-directed hemodynamic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed hemodynamic management group (G group)
Study: 24794140
Drug: Detectable cTnI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detectable cTnI levels at both time points (≥0.01 µg/L)
Study: 23061619
Drug: Monthly feedback
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly feedback on ventilator care bundle (VCB) compliance
Study: 7963789
Drug: Codeine Contin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine Contin 100 mg every 12 hr
Study: 7963789
Drug: Codeine Contin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine Contin 200 mg every 12 hr
Study: 7963789
Drug: Codeine Contin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine Contin 300 mg every 12 hr
Study: 7963789
Drug: Acetaminophen plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen plus codeine (600 mg/60 mg) every 6 hr
Study: 7963789
Drug: Codeine Contin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine Contin 150 mg every 12 hr
Study: 16192479
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg per day)
Study: 21220619
Drug: 0.7-mg DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7-mg DEX implant
Study: 21220619
Drug: 0.35-mg DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.35-mg DEX implant
Study: 19321584
Drug: High milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High milk consumption (4 x 236 mL/d)
Study: 19321584
Drug: Low milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low milk consumption (1 x 236 mL/d)
Study: 17042662
Drug: N-acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (600 mg BID orally, 4 doses)
Study: 17042662
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous fluid hydration
Study: 12772815
Drug: Timolol gel-forming
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol gel-forming solution and latanoprost (tim/latan)
Study: 3067105
Drug: Prostacyclin sodium
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacyclin sodium (2.5-5.0 ng/kg/min) administered intravenously once daily during 2 weeks in 6-hour infusions
Study: 3067105
Drug: Placebo (glycine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glycine buffer) administered intravenously once daily during 2 weeks in 6-hour infusions
Study: 28754504
Drug: Health messaging
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health messaging intervention focused on provider communication about vaccination for HPV vaccine.
Study: 28754504
Drug: Health messaging
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health messaging intervention focused on provider communication about vaccination for influenza vaccine.
Study: 28494175
Drug: Plasmapheresis (supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmapheresis (supportive treatments + plasmapheresis)
Study: 28494175
Drug: Supportive treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive treatments (Control group)
Study: 21420417
Drug: ACWY-TT co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACWY-TT co-administered with DTaP-HBV-IPV/Hib
Study: 9842243
Drug: Amikacin/metronidazole combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin/metronidazole combination
Study: 8018396
Drug: Domperidone 60
Normalized name: domperidone 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 60 mg suppositories every 4 h
Study: 8018396
Drug: Prochlorperazine 25
Normalized name: prochlorperazine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 25 mg suppositories every 4 h
Study: 2904464
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G and sulphadiazine for 5 days postoperatively
Study: 23958073
Drug: EZ-Blocker
Normalized name: Jock-Eze
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EZ-Blocker
Study: 25288038
Drug: Intermittent normobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent normobaric hyperoxia (InHO) for 4 hours daily for 2 weeks
Study: 23960180
Drug: Rituximab maintenance
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab maintenance for 8 months, once every 2 months for a total of four doses
Study: 18192898
Drug: 15-mg NRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-mg NRT transdermal patch for 8 weeks
Study: 18192898
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (NRT)
Study: 18192898
Drug: NRT transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT transdermal patch
Study: 16582058
Drug: Brief therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief therapy
Study: 12642264
Drug: Low-energy shock
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy shock wave treatment (3 applications of 2100 impulses)
Study: 10955372
Drug: Celiprolol (0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (0.30 mg/kg IV)
Study: 10955372
Drug: Atenolol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (0.15 mg/kg IV)
Study: 1624927
Drug: Carbamazepine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (400 mg)
Study: 1624927
Drug: Carbamazepine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (800 mg) and 400 mg
Study: 29877227
Drug: Paprika xanthophylls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paprika xanthophylls (9 mg) administered daily for 5 weeks
Study: 29877227
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered daily for 5 weeks
Study: 26523330
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg triptorelin
Study: 26523330
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg triptorelin
Study: 23539724
Drug: 1 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg ACTH(1-24) intravenous stimulation test
Study: 23539724
Drug: 250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 μg ACTH(1-24) intramuscular stimulation test
Study: 20065185
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg/d plus risedronate 35 mg/wk orally (A + R)
Study: 20065185
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg/d plus placebo (A + P)
Study: 20065185
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg/d plus risedronate 35 mg/wk orally (A + R) in high-risk group
Study: 15570651
Drug: tramadol/APAP (tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: tramadol/APAP (tramadol 37.5 mg/acetaminophen 325 mg)
Study: 9230863
Drug: Preincisional bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincisional bupivacaine infiltration (40 mL of 0.25% bupivacaine 5 minutes before incision)
Study: 9230863
Drug: Postincisional bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postincisional bupivacaine infiltration (40 mL of 0.25% bupivacaine immediately after approximation of the fascia)